This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg. Active years: 2015.
Company Filing History:
1 out of 159 
1 out of 63 
Years Active: 2015
Title: Thilo Welsch: Innovator in Cancer Treatment
Introduction
Thilo Welsch is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer research, particularly in the treatment of pancreatic cancer. His innovative work has led to the development of a patent that addresses critical challenges in cancer therapy.
Latest Patents
Thilo Welsch holds a patent for "Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer." This invention focuses on compounds that inhibit CD95 signaling in pancreatic cancer cells. The patent outlines the potential for these compounds to be used in medicaments aimed at preventing and treating pancreatic cancer. Additionally, it discusses the prevention of cancer cell migration and inflammatory reactions. The invention also includes methods for identifying such compounds and formulating them into effective medicaments.
Career Highlights
Throughout his career, Thilo Welsch has been associated with prestigious institutions such as Ruprecht-Karls-Universität Heidelberg and Deutsches Krebsforschungszentrum. His work in these organizations has been pivotal in advancing cancer research and treatment methodologies.
Collaborations
Thilo Welsch has collaborated with esteemed colleagues, including Susanne Kleber and Ignacio Sancho-Martinez. These partnerships have enriched his research and contributed to the development of innovative solutions in cancer treatment.
Conclusion
Thilo Welsch's contributions to cancer research, particularly through his patent on CD95 signaling inhibitors, highlight his commitment to improving treatment options for pancreatic cancer. His work continues to inspire advancements in medical science and offers hope for better therapeutic strategies.